Thomas Noel, MD
Cardiovascular Disease · Tallahassee, FLNPI 1124147467
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Medtronic at 31.6% of the total. Reporting peaked in 2022 at $20,841 and has fallen 82.6% since, to $3,626 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 550 payments — averaging $157.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$27K
- Edwards Lifesciences$20K
- Cardiovascular Systems Inc.$17K
- Abbott$13K
- Boston Scientific$3K
- Abiomed$1K
- plus $5K from 35 others
Across 270 payments — averaging $4557.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$813K
- Abbott$235K
- Edwards Lifesciences$72K
- Cardiovascular Systems Inc.$51K
- Shockwave Medical, Inc$39K
- Bayer$21K
What the payments were for
- Consulting fees$16,66019%
- Speaking & faculty fees$36,24042%
- Grants$5,3346%
- Travel & lodging$9,15511%
- Food & beverage$18,99222%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 134 | $27,323 |
| Edwards Lifesciences | 66 | $19,742 |
| Cardiovascular Systems Inc. | 20 | $17,499 |
| Abbott | 67 | $13,344 |
| Boston Scientific | 49 | $2,601 |
| Abiomed | 32 | $1,266 |
| Inari Medical, Inc. | 44 | $1,022 |
| Penumbra, Inc. | 31 | $656 |
| Shockwave Medical, Inc | 7 | $435 |
| Amgen | 18 | $338 |
| Cardiac Dimensions, Inc. | 2 | $214 |
| Angiodynamics, Inc. | 4 | $201 |
| Johnson & Johnson | 13 | $191 |
| Philips North America LLC | 3 | $190 |
| Silk Road Medical, Inc. | 2 | $160 |
| Cardiva Medical, Inc. | 7 | $151 |
| Pfizer | 9 | $118 |
| W. L. Gore & Associates, Inc. | 4 | $109 |
| Terumo Medical Corporation | 1 | $96 |
| E.r. Squibb & Sons, L.L.C. | 5 | $91 |
| Stryker | 3 | $86 |
| Canon Medical Systems USA, Inc. | 1 | $75 |
| Biosense Webster, Inc. | 2 | $68 |
| Opsens Inc. | 1 | $43 |
| ZOLL Circulation Inc | 3 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Biotronik Inc. | 2 | $39 |
| AstraZeneca | 3 | $34 |
| Boehringer Ingelheim | 2 | $28 |
| Merck | 1 | $20 |
| Haemonetics Corporation | 1 | $20 |
| Bard Peripheral Vascular, Inc. | 1 | $18 |
| Elutia, Inc. | 2 | $18 |
| Cvrx, Inc. | 1 | $18 |
| Teleflex LLC | 1 | $15 |
| Bayer | 1 | $13 |
| EKOS Corporation | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $12 |
| Portola Pharmaceuticals, LLC | 1 | $12 |
| Procyrion, Inc. | 1 | $11 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Coronary Orbital Atherectomy System$17,265
- COREVALVE EVOLUT R$15,259
- Edwards SAPIEN 3 Transcatheter Heart Valve$13,790
- CoreValve Evolut$8,659
- MitraClip System$5,753
- Mitra Clip system$3,231
- Watchman$1,272
- EVOQUE$1,016
- AMPLATZER Occluders$871
- PASCAL$685
- Omnilink Elite vascular stent system$443
- Impella$386
- Indigo System$246
- GENERAL - STRUCTURAL HEART$227
- GENERAL - THERAPIES$222
- FLOWTRIEVER CATHETER, S$201
- CT THROMBECTOMY SYSTEM KIT$201
- MO.MA ULTRA$191
- SYMPLICITY G3$176
- Vascular Lithotripsy$170
How this compares
$86,382 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 325 | $277,794 |
| EntrestoSacubitril/Valsartan | 251 | $238,324 |
| JardianceEmpagliflozin | 245 | $198,114 |
| Repatha SureclickEvolocumab | 221 | $187,525 |
| FarxigaDapagliflozin Propanediol | 122 | $84,232 |
| XareltoRivaroxaban | 41 | $31,415 |
| BrilintaTicagrelor | 32 | $17,959 |
| Metoprolol Succinate | 495 | $9,630 |
| Rosuvastatin Calcium | 655 | $8,636 |
| Icosapent Ethyl | 20 | $7,706 |
| Ranolazine ErRanolazine | 71 | $6,481 |
| Atorvastatin Calcium | 329 | $4,906 |
| Carvedilol | 389 | $4,436 |
| Ezetimibe | 190 | $4,330 |
| Losartan Potassium | 359 | $4,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $118 | $277,794325 claims |
| Boehringer IngelheimJardiance | $28 | $198,114245 claims |
| AstraZenecaFarxiga, Brilinta | $34 | $102,191154 claims |
| Johnson & JohnsonXarelto | $191 | $31,41541 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Tallahassee
- Gian-Carlo GioveTallahassee$231K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.